ATyr Pharma: FDA Accepts IND Application On Phase 2 Study For COVID-19; Stock Up

aTyr Pharma Inc. (LIFE) said Tuesday that the U.S. Food and Drug Administration has accepted its Investigational New Drug or IND application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications.

In Tuesday pre-market trade, LIFE is trading at $4.02 up $0.93 or 30.10 percent.

The company believes there is strong scientific rationale for the development of ATYR1923 to treat COVID-19 patients

Many COVID-19 patients with severe disease experience serious, sometimes fatal, respiratory complications caused by an excessive inflammatory response in the lung, primarily driven by T-cells.

The inflammatory lung injury related to COVID-19 may be similar to that of interstitial lung diseases, or ILDs, for which ATYR1923 is currently being investigated.

The company noted that the phase 2 clinical trial will be a randomized, double blind, placebo-controlled study with ATYR1923 in 30 confirmed COVID-19 positive patients at up to 10 centers in the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT